Evaluate Efficacy and Safety of LACUDY for Improving Vaginal Environment in Breast Cancer Patient
Status:
Not yet recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
Adjuvant hormone treatments for early breast cancer are associated with frequent bothersome
side effects with major negative impact on patients' quality of life and treatment adherence.
Patients most commonly report menopausal symptoms including vaginal dryness, vaginal
bleeding, and dyspareunia. Even though previous studies have reported that estrogen topical
agent relives these symptoms, non-hormonal therapy should be considered first due to concerns
about the role of estrogen in breast cancer development. Therefore, this trial is planned to
evaluate the efficacy and safety of LacuD (hyaluronic acid, lactic acid and alginate) in the
vaginal environment of breast cancer patients receiving hormone therapy.